The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) was $5.96 for the day, up 4.20% from the previous closing price of $5.72. In other words, the price has increased by $4.20 from its previous closing price. On the day, 0.71 million shares were traded. SONN stock price reached its highest trading level at $6.5 during the session, while it also had its lowest trading level at $5.6001.
Ratios:
Our analysis of SONN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.26.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SONN now has a Market Capitalization of 40691020 and an Enterprise Value of 40003476. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.69. Its current Enterprise Value per Revenue stands at 40.003 whereas that against EBITDA is -2.848.
Stock Price History:
The Beta on a monthly basis for SONN is 1.42, which has changed by 0.020547986 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, SONN has reached a high of $19.30, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is 39.07%, while the 200-Day Moving Average is calculated to be 159.46%.
Shares Statistics:
SONN traded an average of 4.36M shares per day over the past three months and 2566300 shares per day over the past ten days. A total of 6.83M shares are outstanding, with a floating share count of 6.56M. Insiders hold about 3.95% of the company’s shares, while institutions hold 2.64% stake in the company. Shares short for SONN as of 1756425600 were 1866078 with a Short Ratio of 0.43, compared to 1753920000 on 1031208. Therefore, it implies a Short% of Shares Outstanding of 1866078 and a Short% of Float of 27.37.
Earnings Estimates
The market rating for Sonnet BioTherapeutics Holdings Inc (SONN) is a result of the insights provided by 1.0 analysts actively involved in the assessment.
Analysts are recommending an EPS of between -$3.46 and -$3.46 for the fiscal current year, implying an average EPS of -$3.46.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for SONN’s current fiscal year. The highest revenue estimate was $1M, while the lowest revenue estimate was $1M, resulting in an average revenue estimate of $1M. In the same quarter a year ago, actual revenue was $18.63k
